Animal health biotechnology firm, Vetigenics, and pharmaceutical company division Merck & Co., Inc.'s Merch Animal Health. Out of the partnership, the two companies will seek to discover and create new therapeutic antibodies for pets' chronic diseases.
The proprietary platform, Vetigenics' Canibody, is intended for dogs only and isolates genetic material called single chain variable fragments which can potentially be targeted for therapies. Because the therapies are created based on genetic material, the likelihood of immune reaction is greatly reduced.
"Vetigenics is thrilled that Merck Animal Health has expressed confidence in Vetigenics' Canibody Platform for the discovery of novel, entirely canine, antibody-based therapeutics," said Adriann Sax, co-founder, and chief executive officer of Vetigenics. "With our platform's highly differentiated qualities, most notably the complete species-specific antibody repertoire as well as the speed in which we can isolate high-value drug candidates, we are confident that combining the power of our platform with Merck Animal Health's exceptional development and commercialization capabilities will result in superior therapeutic antibodies to treat companion animals."
List
Add
Please enter a comment